Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | The impact of COVID-19 on CAR-T therapy

Bruce Levine • 28 May 2020
General

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, updates us on the impact on COVID-19 on the delivery of CAR-T therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Bruce Levine

1:15
CAR-T therapy: where is it going?
Bruce Levine • 28 May 2020
1:20
ISCT 2020: Moving ahead at full speed session - what can delegates look forward to?
Bruce Levine • 28 May 2020
1:00
ISCT 2020: looking forward to advances and emerging technologies in immune-mediated cancer therapy
Bruce Levine • 28 May 2020
1:29
Translation from academia to industry: manufacturing of CAR T-cells
Bruce Levine • 30 Jan 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals